These data indicated the CD6-ADC has a significantly heightened treatment efficacy (Figure 3) and much lower level of effective dose than the parent “naked” anti-CD6 mAb in treating autoimmune diseases, which could lead to many benefits, such as reduced costs and decreased potential side effects. Here, CD6 is linked to autoimmune disease.